Digoxin
LANOXIN
Cardiac Glycoside
NADAC/unit
$0.1126
No Shortage
Tier 1: 82.7%
PA Req: 3.6%
10 Manufacturers
18 ANDAs
1 INDICATIONS & USAGE Digoxin is a cardiac glycoside indicated for: Treatment of mild to moderate heart failure in adults. ( 1.1 ) Increasing myocardial contractility in pediatric patients with hea....
vs. brand LANOXIN: Generic saves up to 99% per unit
Market Intelligence
2024-04-24 Class III Recall: Novitium Pharma LLC
2024-03-27 Class III Recall: Novitium Pharma LLC
Generic Manufacturers
ADVANZ PHARMA (US) CORPAMICI PHARMA INCAUROBINDO PHARMA LTDCOVIS PHARMA GMBHHIKMA INTERNATIONAL PHARMACEUTICALS LLCHIKMA PHARMACEUTICALS USA INCJEROME STEVENS PHARMACEUTICALS INCNOVITIUM PHARMA LLCRISING PHARMA HOLDING INCSANDOZ INCSUN PHARMACEUTICAL INDUSTRIES INCVISTAPHARM LLC
Explore in the Ecosystem
Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.